NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis $0.33 -0.02 (-5.78%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About Oragenics Stock (NYSE:OGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oragenics alerts:Sign Up Key Stats Today's Range$0.31▼$0.3550-Day Range$0.30▼$1.4452-Week Range$0.29▼$7.74Volume418,348 shsAverage Volume330,350 shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More… Don’t Miss Out! Get 2 Hot AI Stocks for Under $10/Share 🚀 (Ad)Artificial Intelligence (AI) stocks are booming, and now is your chance to get in on the action — without breaking the bank! We’ve just uncovered 2 must-buy AI stocks trading for under $10/share, and they’re showing serious potential for growth.Click here to get your FREE report delivered instantly! Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address OGEN Stock News HeadlinesStockNews.com Begins Coverage on Oragenics (NYSE:OGEN)October 22 at 3:02 AM | americanbankingnews.comOragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas SummitOctober 18, 2024 | globenewswire.comAre You Holding the Winning Hand in the Copper Market?Are You Holding the Winning Hand in the Copper Market?October 24, 2024 | Market JAR (Ad)Oragenics inks sales agreement for at-the-market stock offeringOctober 17, 2024 | investing.comBioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion TreatmentOctober 9, 2024 | msn.comOragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial PreparationOctober 9, 2024 | globenewswire.comInvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002October 8, 2024 | msn.comEXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug CandidateOctober 8, 2024 | benzinga.comSee More Headlines OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed this year? Oragenics' stock was trading at $6.1382 at the beginning of 2024. Since then, OGEN shares have decreased by 94.7% and is now trading at $0.3260. View the best growth stocks for 2024 here. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) announced its quarterly earnings results on Friday, August, 9th. The company reported ($0.51) earnings per share (EPS) for the quarter. When did Oragenics' stock split? Shares of Oragenics reverse split before market open on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT). Company Calendar Last Earnings8/09/2024Today10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGEN Previous SymbolNYSE:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,660,000.00 Net MarginsN/A Pretax Margin-243,950.00% Return on Equity-1,077.64% Return on Assets-408.52% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.17 Sales & Book Value Annual Sales$40,000.00 Price / Sales45.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book0.53Miscellaneous Outstanding Shares5,580,000Free Float4,208,000Market Cap$1.82 million OptionableN/A Beta0.45 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:OGEN) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredAmerica’s Election NightmareThanks to a new law signed by President Biden, a small group of powerful people could decide who is installed ...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.